Vitiligo
☆ AI Dermatology — Free Service
I 2022 Stiftung Warentest-resultaterne fra Tyskland var forbrugernes tilfredshed med ModelDerm kun lidt lavere end med betalte telemedicinske konsultationer.
I 2022 Stiftung Warentest-resultaterne fra Tyskland var forbrugernes tilfredshed med ModelDerm kun lidt lavere end med betalte telemedicinske konsultationer.
Vitiligo på fingrene er sværere at behandle end i andre områder. Ud over at være kosmetisk uønsket, er vitiligo en normal, ikke‑smitsom tilstand. Inden for dermatologi er den mest effektive behandling fototerapi eller laserbehandling (excimer) 2–3 gange om ugen i mindst ét år. Hvis du af økonomiske årsager eller på grund af travlhed har svært ved at komme ofte på hospitalet, kan du overveje en fototerapimaskine, der er godkendt til hjemmebrug.
Øjenlågsvitiligo
Vitiligo på hånden
relevance score : -100.0%
ReferencesVitiligo er en almindelig hudsygdom, som forårsager hvide pletter på huden på grund af tab af melanocytter. Nyere forskning viser, at det er en autoimmun sygdom. Selvom den ofte betragtes som et kosmetisk problem, kan den påvirke både mentalt velvære og dagligdagen i høj grad. I 2011 klassificerede eksperter en type, kaldet segmental vitiligo, som adskilt fra de øvrige former.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Patienter med aktiv vitiligo har flere behandlingsmuligheder, såsom systemiske glukokortikoider, fototerapi og systemiske immunsuppressiva. Stabile vitiligopatienter kan finde lindring fra topiske kortikosteroider, topiske calcineurinhæmmere, fototerapi og transplantationsprocedurer. Nylige fremskridt i forståelsen af vitiligos underliggende processer har ført til udviklingen af målrettede terapier. I øjeblikket er JAK‑hæmmere de mest lovende og tilbyder god tolerabilitet og funktionelle resultater, på trods af risikoen for at aktivere latente infektioner og systemiske bivirkninger, der er almindelige med andre immunsuppressive midler. Igangværende forskning har til formål at identificere nøglecytokiner involveret i vitiligos udvikling (IFN‑γ, CXCL10, CXCR3, HSP70i, IL‑15, IL‑17/23, TNF). Blokering af disse cytokiner har vist lovende resultater i dyremodeller og hos nogle patienter. Derudover pågår undersøgelser af miRNA‑baserede terapier og adoptiv Treg‑celleterapi.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Der findes ingen kendt kur mod vitiligo. For personer med lys hud er solcreme og makeup typisk det, der anbefales. Andre behandlingsmuligheder kan omfatte steroidcremer eller fototerapi.
○ Behandling
#Phototherapy
#Excimer laser
#Tacrolimus ointment